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Abstract
Background: The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of
mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence
of biopsy or complete excision.
Methods: Two well-established population models evaluated six possible DCIS natural history submodels. The
submodels assumed 30%, 50%, or 80% of breast lesions progress from undetectable DCIS to preclinical screen-
detectable DCIS; each model additionally allowed or prohibited DCIS regression. Preclinical screen-detectable DCIS
could also progress to clinical DCIS or invasive breast cancer (IBC). Applying US population screening dissemination
patterns, the models projected age-specific DCIS and IBC incidence that were compared to Surveillance,
Epidemiology, and End Results data. Models estimated mean sojourn time (MST) in the preclinical screen-detectable
DCIS state, overdiagnosis, and the risk of progression from preclinical screen-detectable DCIS.
Results: Without biopsy and surgical excision, the majority of DCIS (64–100%) in the preclinical screen-detectable
state progressed to IBC in submodels assuming no DCIS regression (36–100% in submodels allowing for DCIS
regression). DCIS overdiagnosis differed substantially between models and submodels, 3.1–65.8%. IBC overdiagnosis
ranged 1.3–2.4%. Submodels assuming DCIS regression resulted in a higher DCIS overdiagnosis than submodels
without DCIS regression. MST for progressive DCIS varied between 0.2 and 2.5 years.
Conclusions: Our findings suggest that the majority of screen-detectable but unbiopsied preclinical DCIS lesions
progress to IBC and that the MST is relatively short. Nevertheless, due to the heterogeneity of DCIS, more research
is needed to understand the progression of DCIS by grades and molecular subtypes.
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Introduction
With the introduction of mammographic screening, the
incidence of ductal carcinoma in situ (DCIS) has in-
creased rapidly due to the ability of mammography to
identify associated microcalcifications. In the absence of
calcifications that are observable by mammography,
DCIS is either undetectable or preclinical, detected inci-
dentally during biopsy of a different lesion, or rarely, de-
tected clinically when it induces fibrosis and produces a
clinical mass. In the USA, DCIS incidence rate among
women older than 40 years increased from 5.6 per 100,
000 women in 1990–1994 to 31.6 per 100,000 women in
2010–2014 [1]. DCIS is regarded as “a neoplastic prolif-
eration of cells within the ductal-lobular structures of
the breast that has not penetrated the myoepithelial-
basement membrane interface” [2]. Although DCIS itself
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is not life-threatening, it can progress to invasive breast
cancer (IBC) if left untreated [3, 4]. The most common
treatment options for DCIS are breast-conserving sur-
gery, usually with breast irradiation, and total mastec-
tomy [5]. Although the detection of DCIS has increased
substantially relative to detection of invasive breast can-
cer, its natural history remains poorly understood. In
particular, there is considerable uncertainty about the
rates of DCIS progression and regression.
To date, two approaches have been used to characterize
DCIS natural history. In the first approach, observational
studies have focused on women with a biopsy-confirmed
diagnosis of DCIS who did not undergo definitive surgery [3,
4, 6–12]. However, because such observational studies report
on outcomes in patients who received core needle or exci-
sional biopsies, the findings do not directly ascertain the un-
observed natural history of progression. To address this
caveat, a second approach uses mathematical models in con-
junction with clinical data and/or data from mammography
screening studies to infer latent disease dynamics [13–16].
Estimates of progression risk and mean sojourn time (MST),
that is, the time from preclinical DCIS to IBC, vary widely
between the two approaches and even between studies of the
same approach. For instance, progression risk estimates are
generally lower for biopsy-treated women in observational
studies (ranging from 12 to 52% [4, 6–12]) than from model-
ing studies (ranging from 61 to 91% [13, 14, 17, 18]).
Due to the residual uncertainty about natural history, the
extent of breast cancer overdiagnosis and overtreatment are
difficult to quantify. Indeed, while researchers generally
accept that a fraction of screen-detected DCIS and IBC le-
sions would not progress to clinical disease if left untreated
[10], estimates of overdiagnosis range from less than 1% [19]
to 37% [13]. Currently ongoing active monitoring trials for
low-risk DCIS patients [20–22] are expected to provide an
estimate of the risk of progression from biopsy-confirmed
DCIS to invasive disease. However, these trials rely on statis-
tical inference rather than direct observation to provide
insight into unobservable natural history dynamics.
Here we developed an alternative modeling approach to
study DCIS natural history. Rather than relying on data
from screening studies, we employed population-based
models of incidence and progression in conjunction with
breast cancer incidence data from the Surveillance, Epi-
demiology and End Results (SEER) program. By compar-
ing two independently developed and validated population
models of breast cancer, and evaluating multiple submo-
dels for each, we explored a range of possible natural his-
tories and projected the resulting extent of overdiagnosis.
Materials and methods
Model description
Two well-established models have been used for this
study, which were developed in the Cancer Intervention
and Surveillance Modeling Network (CISNET): model D
(Dana-Farber Cancer Institute) [23, 24] and model E
(Erasmus MC, University Medical Center Rotterdam)
[25, 26].
Model D is an analytical model that estimates breast
cancer incidence and mortality as a function of disease
natural history, detection process, and treatment [23,
27]. Details of IBC [24, 28] and DCIS [23, 29] modeling
have been reported previously. DCIS natural history pa-
rameters were estimated using data from the Norwegian
breast cancer screening program. Details of model D
and estimation of model parameters can be found in
Additional file 1.
Model E is a discrete event-driven micro-simulation
model that simulates independent life histories of
women using a parallel universe approach [25, 26]. This
means that there are two identical female populations
whereby one population undergoes screening and one
population does not have screening. Recently, model E
has been extended by including DCIS [30]. The DCIS
model component is stage-specific whereby preclinical
undetectable DCIS can be allowed to enter a regression
state or progress to preclinical screen-detectable DCIS,
clinical DCIS, or preclinical IBC. The natural history pa-
rameters for DCIS were estimated through calibration
with DCIS SEER data. A more extensive description of
model E can be found in Additional file 2.
Both models have been extensively evaluated on US
breast cancer incidence and mortality trends [31–33]
and used to estimate benefits and harms of mammog-
raphy screening [34]. Both models have been used to in-
form breast cancer screening recommendations, for
instance, by the US Preventive Services Task Force
(USPSTF) [35]. A more detailed description of models D
and E can be found on https://resources.cisnet.cancer.
gov/registry/packages/filter/Breast/, in the Additional
files and elsewhere [23, 34].
Submodels
In total, 6 parallel submodels were developed (repre-
sented in Fig. 1), each with its own assumptions com-
mon for both model D and model E. This includes three
different proportions of DCIS lesions in the preclinical
undetectable DCIS state progressing to preclinical
screen-detectable DCIS (i.e., 30%, 50%, and 80%), and
the ability of DCIS to regress [23, 25]. The structure of
the DCIS components in models D and E is similar as
they both assume that normal breast tissue can progress
to preclinical DCIS which is undetectable as depicted in
Fig. 1. From there onwards, preclinical undetectable
DCIS can become screen-detectable or evolve into pre-
clinical IBC. Screen-detectable DCIS can progress to
preclinical IBC (P1) or clinical DCIS (P2), whereas pre-
clinical IBC can develop into clinical IBC possibly
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leading to breast cancer death. The death state unrelated
to breast cancer can result from any non-breast cancer
death state in Fig. 1.
Input parameters
Estimated from Breast Cancer Surveillance Consortium
(BCSC) data, mammography sensitivity for detecting
DCIS were set to 0.45, 0.55, 0.70, and 0.85 for the
periods 1975–1984, 1985–1999, 2000–2009, and 2010
onwards, respectively [24]. This reflects the improve-
ment in mammography sensitivity over time in the USA
[36]. Furthermore, both models used screening dissem-
ination patterns in the USA over time until 2010 and ex-
trapolated patterns thereafter [37]. Other common input
parameters, such as birth tables, life tables, and age-
period-cohort estimates of breast cancer incidence in the
Fig. 1 Graphical representation of the DCIS model and its submodels. The figure depicts the states that are included in the model. The dotted
arrow from the state preclinical screen-detectable DCIS to the state no breast cancer is included into the submodels where DCIS regression is
allowed. The proportion of preclinical undetectable DCIS that progresses to preclinical screen-detectable DCIS can be 30%, 50%, or 80%. Different
model assumptions on the natural history of DCIS are included for each submodel
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absence of screening, are described in a previous publi-
cation [37].
Model outcomes
The models estimated rates of overdiagnosis of DCIS
and IBC (per 100,000 women) and MSTs in the screen-
detectable preclinical DCIS state. DCIS overdiagnosis
was defined as a screen-detected DCIS case that would
not have been found in the absence of screening as it
would not have progressed to clinical DCIS or clinical
IBC in the remaining lifetime of the woman. Similarly,
overdiagnosed IBC was defined as a screen-detected IBC
case that would not have been found in the absence of
screening as it would not have developed into clinical
IBC in the remaining lifetime of the woman.
We also calculated overdiagnosis for DCIS, IBC, and
DCIS and IBC combined by dividing the number of
overdiagnosed cases by the total number of screen-
detected and clinically detected cases. The MST was de-
fined as the number of years in which DCIS is screen-
detectable before it progresses to another state, which
could be the preclinical IBC state, clinical DCIS state, or
normal tissue (DCIS regression). For model D, the MST
was an input parameter (Additional file 1) while it was
an output for model E.
Statistical analysis
We generated age-specific and age-adjusted (between
ages 30 and 79 years) data for birth cohorts born be-
tween 1890 and 1996. The projected age-adjusted inci-
dence for DCIS and IBC were compared with SEER
data. A chi-square test was performed to assess the
goodness of fit between the projected incidence esti-
mates and observed data of DCIS and IBC for the calen-
dar year 1975 to 2015.
Results
Comparing SEER data and projected incidence for DCIS
and IBC
Model D projected DCIS incidence that matched the
SEER data relatively well for all submodels as indicated
by the goodness-of-fit measures (Table 1). The model fit
was better for earlier calendar years (Fig. 2). Model D
showed higher DCIS incidence in later years when re-
gression was allowed compared to no regression, except
for submodel 3 where the incidence was similar regard-
less of DCIS regression. Model E also generated DCIS
incidence that matched the SEER data relatively well as
shown in Table 1, except for submodel 1b. The best fit
for model E was submodels 2a and 2b where 50% of the
DCIS lesions in the preclinical undetectable DCIS state
progress to preclinical screen-detectable DCIS state.
Model E had lower DCIS incidences when regression
was allowed in submodels 2 and 3 but not 1. IBC
incidence projected from both models D and E matched
the SEER data relatively well for all submodels (Fig. 3).
Mean sojourn times
Models D and E estimated that the MSTs of screen-
detectable preclinical DCIS lesions ranged 0.2–7.7 years,
but mostly less than 4 years for the different submodels
(Table 1). MST estimates varied by submodels and by
DCIS progression path (i.e., progress to preclinical IBC,
clinical DCIS, or regress). Model D’s estimates showed a
trend towards a shorter or equal MSTs in submodel 3
(versus submodels 2 and 1). This trend was not obvious in
model E. The MSTs of the lesions that progressed to pre-
clinical IBC were shorter when DCIS regression was
allowed. This trend was also seen for the lesions that will
progress to clinical DCIS in all submodels for model E
and in submodel 1 for model D. The MSTs of the lesions
that regressed were 1.5 years in all submodels of model D
and varied between 0.6 and 4.0 years in model E.
Proportion of DCIS cases progressing to other states
Figure 4 displays estimated proportions of DCIS lesions
in the preclinical DCIS state that progress to other states
by age for the 1930 birth cohort in the absence of
screening, biopsy, and surgical excision. Assuming no
DCIS regression, most submodels showed a large pro-
portion of DCIS progressing to preclinical IBC, ranging
from 64 to 100%. For submodels that allowed DCIS re-
gression, this proportion ranged from 36 to 100%.
Throughout all submodels, the proportion progressing
to clinical DCIS varied from 0 to 36%. In submodels
where DCIS regression was allowed, the proportion of
DCIS regressing was higher than the proportion progres-
sing to clinical DCIS. Furthermore, Fig. 4 shows that
younger women have a larger proportion progressing
preclinical IBC compared to older women. Similar pro-
portions of DCIS progression and age-specific trends
were observed in all other birth cohorts.
Overdiagnosis of DCIS and IBC
In both models, the level of DCIS overdiagnosis in-
creased as a function of age and calendar year as mam-
mogram use was more widely disseminated. Both
models found a higher overdiagnosis rate when DCIS re-
gression was assumed. For example, model D estimated
DCIS overdiagnosis to be 3.1–4.8% across submodels
without DCIS regression; overdiagnosis increased to
13.3–19.3% when regression was allowed (Table 1).
Model E had a similar trend, although the level of DCIS
overdiagnosis was higher (35 to 66%). Combining DCIS
and IBC, the level of overdiagnosis varied between 2.5
and 10.5%. Furthermore, both models estimated that
IBC overdiagnosis increased with age (see Fig. 5).
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Discussion
As the natural history of DCIS is mostly unknown, it is
challenging to pinpoint a unique DCIS model. This study
investigated different DCIS natural history models and se-
lected six plausible models that could explain DCIS and
IBC incidence in the USA. Unlike other attempts to model
the natural history of DCIS [18, 19, 38], our extensive
work involved two-established modeling groups, several
submodels, multiple birth cohorts, and a 40-year time
span with the mammogram dissemination patterns ob-
served in the USA [39]. Our modeling work also showed
that several different natural history models fit the ob-
served trends, making any firm conclusions about the
DCIS natural history based on observation data difficult.
Most submodels in our study indicated that the major-
ity of unexcised screen-detectable preclinical DCIS le-
sions progress to IBC. This agrees with previous
modeling studies that have estimated progression vary-
ing from 61–91% [13, 14, 17, 18]. Notably, results from
our submodels showed that younger women may have a
higher proportion of progression from unexcised screen-
detectable DCIS to preclinical IBC. A possible explan-
ation is that young women tend to have a more ag-
gressive type of DCIS which is more likely to
progress to IBC [3]. For women older than 50 years,
our study found that the proportion of screen-
detectable DCIS progressing to preclinical IBC to be
between 36 and 99%. Furthermore, our study showed
that the proportion of screen-detectable DCIS that
could regress varied between 0 and 56%. These re-
sults are consistent with previous modeling studies
that have estimated the proportion of DCIS regression
was between 1 and 37% [13, 14, 40].
Observational studies of women who did not receive
definitive surgery after diagnosis with DCIS have found
lower rates of progression invasive cancer, ranging from
12 to 54% [4, 6–12]. However, these studies are not dir-
ectly comparable to modeling results because they do
not capture non-screen detected preclinical DCIS. In-
deed, only modeling studies can capture progression
rates of lesions uninterrupted by biopsy or other treat-
ment. Lower progression rates in observational studies
could be due to a number of factors. First, there is a
chance of complete removal of the DCIS lesion during
biopsy. This disruption of natural history will bias esti-
mates, resulting in a lower estimated proportion of DCIS
progressing to IBC and a non-observed sojourn time. In
addition, mammography-detected lesions usually contain
calcifications, and it remains unclear whether DCIS with
and without calcification have the same natural history.
Finally, inflammation of the stroma caused by the biopsy
might alter the natural course of DCIS [41].
Table 1 Outcomes for three DCIS submodels with and without regression during 1975–2015 for women aged 30–79 years
Df 1a noReg 1b wReg 2a noReg 2b wReg 3a noReg 3b wReg
Goodness-of-fit
Deviance (observed-estimated)^2
DCIS deviance (p value*) Model D 40 665 (0.98) 1182 (0.82) 1242 (0.79) 2168 (0.15) 1307 (0.77) 1121 (0.89)
Model E 40 1505 (0.18) 2071 (0.004) 698 (0.95) 926 (0.81) 1637 (0.12) 1064 (0.56)
IBC deviance (p value*) Model D 40 2734 (1.00) 2499 (1.00) 3406 (1.00) 2585 (1.00) 3116 (1.00) 3527 (1.00)
Model E 40 3183 (1.00) 4386 (0.98) 6071 (0.86) 5388 (0.95) 5921 (0.80) 2510 (1.00)
Mean sojourn time
MST of preclinical screen-detectable DCIS
before progressing to preclinical IBC
Model D 2.5 1.5 0.7 0.5 0.4 0.2
Model E 0.9 0.5 0.8 0.4 1.0 0.6
MST of preclinical screen-detectable DCIS
before progressing to clinical DCIS
Model D 2.5 1.5 1.9 1.9 1.9 1.9
Model E 3.9 3.1 4.5 0.9 7.7 1.4
MST of preclinical screen-detectable
DCIS before regressing
Model D NA 1.5 NA 1.5 NA 1.5
Model E NA 4.0 NA 1.3 NA 0.6
Overdiagnosis
% DCIS overdiagnosis Model D 4.8% 19.3% 3.4% 13.3% 3.1% 19.1%
Model E 35.2% 65.8% 33.7% 62.2% 33.6% 47.8%
% IBC overdiagnosis Model D 2.4% 2.4% 2.4% 2.4% 2.4% 2.4%
Model E 1.4% 1.4% 1.4% 1.4% 1.3% 1.4%
% DCIS + IBC overdiagnosis Model D 2.7% 5.1% 2.5% 4.2% 2.5% 5.0%
Model E 6.0% 10.5% 5.8% 9.7% 6.7% 8.6%
DCIS ductal carcinoma in situ, IBC invasive breast cancer, NA not available, df degree of freedom, noReg model without DCIS regression, wReg model with
DCIS regression
*p values from chi-square tests; mean sojourn times are expressed in number of years
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Fig. 2 DCIS incidence and overdiagnosis. Each graph includes SEER data and 2 submodels (1 without DCIS regression and 1 with DCIS
regression). The projections include women in the age group 30–79 years. noReg, model without DCIS regression; wReg, model with DCIS
regression; OD, overdiagnosis
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Fig. 3 IBC incidence and overdiagnosis. Each graph includes SEER data and 2 submodels (1 without DCIS regression and 1 with DCIS regression).
The projections include women in the age group 30–79 years. noReg, model without DCIS regression; wReg, model with DCIS regression;
OD, overdiagnosis
Chootipongchaivat et al. Breast Cancer Research           (2020) 22:53 Page 7 of 12
Fig. 4 Proportion of DCIS cases progressing to other states. Stacked bar plots showing the proportion of preclinical screen-detectable DCIS
progressing to preclinical invasive breast cancer (P1), clinical DCIS (P2), or no breast cancer (P3; regression). P1, P2, and P3 are represented by
blue, red, and green bars, respectively. Simulated birth cohort 1930
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An interesting finding from our study was that across
all submodels the MSTs were relatively short, in particu-
lar when assuming DCIS regression. This agrees with
previous modeling studies estimating MSTs between 0.5
months to 2.6 years under the assumption that IBC pro-
gresses through screen-detectable DCIS [13, 17–19].
Similar to other modeling studies, MSTs tend to be
shorter for preclinical screen-detectable DCIS progres-
sing to preclinical IBC compared to other health states
such as clinical DCIS or going into regression [13, 19].
Although our results show a similar direction as previ-
ous studies, all DCIS modeling studies are subject to
Fig. 5 Overdiagnosis by age. Calendar year 2010. Each graph includes overdiagnosis for DCIS and IBC. DCIS, ductal carcinoma in situ; IBC, invasive
breast cancer; noReg, submodel without DCIS regression; wReg, with DCIS regression
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considerable residual uncertainty of the estimates.
Nevertheless, short MSTs for preclinical screen-
detectable DCIS progressing to clinical DCIS and IBC
could guide discussions on screening intervals in propos-
ing screening guidelines. With regard to treatment, it re-
mains difficult to make suggestive recommendations
about treatment for DCIS patients unless a clinical factor
and/or molecular signatures can be identified, providing
insight into which women can avoid or postpone treat-
ment [42].
The level of overdiagnosis of breast cancer is challen-
ging to quantify, especially for screen-detected DCIS.
Overdiagnosis estimates for DCIS varied between
models D and E, with model D showing consistently
lower level of DCIS overdiagnosis compared to model E
and previous studies [13, 19, 43]. This difference is prob-
ably due to model D having shorter estimated MSTs in
preclinical DCIS, and high progression rates to IBC,
leading to lower DCIS overdiagnosis estimates. In con-
trast to model D where the sojourn time is used as an
input, model E estimates the mean sojourn times for
every submodel. Model D used the Norwegian breast
cancer screening data to estimate the DCIS model pa-
rameters, while model E was developed on US data only.
Our study showed that DCIS overdiagnosis varied
from 13 to 66% when DCIS regression was allowed and
3 to 35% when assuming no DCIS regression. Yen et al.
[13] also estimated that the proportion of the screen-
detected DCIS that is non-progressive (not progressing
to IBC) varies from 19 to 46% in the prevalence screen
and from 3 to 21% in the first subsequent screen. An-
other study by Seigneurin et al. estimated that 20.3%
(95% CI, 3.0–38.9%) of in situ cancer was overdiagnosed,
assuming that non-progressive in situ cancer remains in
the preclinical phase [44]. With regard to IBC in our
study, overdiagnosis was on average between 1.3 and
2.4% regardless of the assumption of DCIS regression
for the age group 30–79 years. This falls in the range of
1–10% for overdiagnosed IBC reported in the systematic
review conducted by Puliti et al. based on European
studies [45]. Despite the variation in estimated DCIS
overdiagnosis levels by submodel, the overall level of
overdiagnosis of DCIS+IBC was not high, ranging 2.5–
10.5%.
Most submodels in this study showed a reasonable fit
with SEER data, indicating that different sets of parame-
ters can match observed breast cancer rates. The ability
to fit population data with varied parameters highlights
the difficulty in providing definitive conclusions on the
natural history of DCIS. This difficulty makes the pend-
ing results of the currently enrolling active monitoring
trials LORD, LORIS, and COMET even more critical
[20–22]. Although these trials focus on the disease pro-
gression of screen-detected, biopsied low-risk lesions,
they will significantly enhance our understanding of
overall clinical management of DCIS. Further research
should focus on the heterogeneity of DCIS in various
age groups as younger women may tend to have a more
aggressive type of DCIS. Also, future modeling work by
DCIS grade, molecular subtype, and inherent factors
such as family history of breast cancer will provide more
specific information on MSTs and progression of the
disease that will contribute to guiding women with spe-
cific features on screening and treatment.
Conclusion
Our study suggested that the majority of unexcised
screen-detectable preclinical DCIS lesions progress to
IBC and that the MSTs are relatively short. Furthermore,
our modeling work also showed that several different
natural history models fit the observed trends, making
any firm conclusions about the DCIS natural history
based on observation data difficult. Due to the hetero-
geneity of DCIS, more research is needed to understand
the progression of DCIS by grades, molecular subtypes,
and certain inherent factors such as family history of
breast cancer.
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